FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation

Coverage, in order

1. 15d ago
   
   Healthline mainstream

   FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation

   The Eli Lilly corporate headquarters in Indianapolis, IN, on August 15, 2024. AJ Mast/Bloomberg via Getty Images The FDA approved a new oral combo drug for a common breast cancer mutation on September 18. The treatment includes Inluriyo (imlunestrant) taken with Verzenio (abemaciclib) for adults…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.